Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932306 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT02932306: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT02932306 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 820 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02932306, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \[EGSS\] of 3 \[moderate\] or 4 \[severe\]).
Primary Outcome
Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.
Interventions
- DRUG IDP-121 Vehicle Lotion
- DRUG IDP-121 Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2015-11-03 |
| Est. Completion | 2017-02-22 |
| Phase | Phase 3 |
What the finished NCT02932306 record still lists
NCT02932306 is an interventional study that assigns participants to a tested intervention. The registered 820 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which IDP-121 Vehicle Lotion is the first listed.
NCT02932306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02932306 about?
NCT02932306 is a clinical study titled "Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris". The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severit...
What is the current status of trial NCT02932306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2015-11-03. Estimated completion is 2017-02-22.
What interventions are being tested in trial NCT02932306?
The interventions under investigation include: IDP-121 Vehicle Lotion (DRUG), IDP-121 Lotion (DRUG).
Who is sponsoring clinical trial NCT02932306?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02932306's enrollment target sits among peer trials
820 404th of 2000 higher than 1,596 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI